Decker D A, Ahmann D L, Bisel H F, Edmonson J H, Hahn R G, O'Fallon J R
JAMA. 1979 Nov 9;242(19):2075-9.
Four hundred thirty-eight patients with metastatic breast cancer treated with nine prospective randomized trials were reviewed to analyze, characterize, and compare those with complete regression (CR) (N=49 [11%]) with those with noncomplete regression (non-CR) (N=389 [89%]). Site of dominant disease was identical in the CR and non-CR patients. However, CR was statistically more likely when the disease-free interval and the postmenopausal status was five years or less. Survival and time to progression occurred at sites of prior dominant disease, except that relapses occurred in the CNS in 14%. Six CR patients received prolonged chemotherapy and were believed to be "cured" when treatment was discontinued; however, all except one have had relapses.
回顾了9项前瞻性随机试验中接受治疗的438例转移性乳腺癌患者，以分析、描述并比较完全缓解（CR）患者（n = 49 [11%]）和非完全缓解（非CR）患者（n = 389 [89%]）。CR组和非CR组患者的主要疾病部位相同。然而，当无病间期和绝经状态为5年或更短时间时，CR在统计学上更有可能出现。生存和疾病进展时间发生在先前主要疾病的部位，不过有14%的复发发生在中枢神经系统。6例CR患者接受了延长化疗，在停止治疗时被认为“治愈”；然而，除1例外，所有患者均复发。
